Skip to main content
34°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
SpringWorks Therapeutics, Inc. - common stock
(NQ:
SWTX
)
41.88
-2.25 (-5.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SpringWorks Therapeutics, Inc. - common stock
< Previous
1
2
3
4
5
6
Next >
No Quick Fix For This Market
March 23, 2025
Despite the pullback, we have found numerous opportunities which we discuss in this video using technical analysis.
Via
Talk Markets
Topics
Stocks / Equities
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
March 16, 2025
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Via
Stocktwits
Assessing SpringWorks Therapeutics: Insights From 6 Financial Analysts
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
Smart Money Is Betting Big In SWTX Options
February 10, 2025
Via
Benzinga
SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?
March 10, 2025
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
Via
Stocktwits
10 Health Care Stocks Whale Activity In Today's Session
February 27, 2025
Via
Benzinga
Top 3 Health Care Stocks You May Want To Dump In February
February 20, 2025
Via
Benzinga
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
February 20, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
February 20, 2025
Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.
Via
Stocktwits
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 14, 2025
Via
Benzinga
SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug
February 12, 2025
SpringWorks' Gomekli wins FDA approval for NF1-related tumors, showing strong efficacy in trials. U.S. launch expected in two weeks, with EU review ongoing.
Via
Benzinga
Exposures
Product Safety
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
February 11, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics
February 11, 2025
Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Crude Oil Rises Sharply; Manhattan Associates Shares Slide
February 10, 2025
Via
Benzinga
Exposures
Fossil Fuels
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
February 10, 2025
Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.
Via
Stocktwits
Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss
February 10, 2025
Via
Benzinga
Rockwell Automation Posts Upbeat Earnings, Joins Insperity, BP, Alibaba And Other Big Stocks Moving Higher On Monday
February 10, 2025
Via
Benzinga
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
January 30, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
January 27, 2025
Via
Benzinga
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
January 13, 2025
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Via
Investor's Business Daily
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
January 12, 2025
These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio?
Via
Benzinga
SpringWorks Therapeutics Stock Gets A RS Rating Lift
January 08, 2025
The Relative Strength (RS) Rating for SpringWorks Therapeutics stock entered a higher percentile Wednesday, as it got a lift from 62 to 76.
Via
Investor's Business Daily
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.